BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21464763)

  • 21. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
    Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
    Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
    Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A
    Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
    Kibbler CC
    Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution.
    Lass-Flörl C; Gunsilius E; Gastl G; Englisch M; Koch G; Ulmer H; Dierich MP; Petzer A
    Ann Hematol; 2003 Sep; 82(9):565-9. PubMed ID: 14504812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
    Warn PA; Sharp A; Morrissey G; Denning DW
    J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiologically documented fungal infections in pediatric patients with acute myeloid leukemia: 12.5-year experience at a single institution.
    Agarwal V; Joyce M
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e528-32. PubMed ID: 24824444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents].
    Finke R
    Mycoses; 1990; 33 Suppl 1():42-54. PubMed ID: 2101864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia].
    Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M
    Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
    Pagano L; Caira M; Candoni A; Offidani M; Fianchi L; Martino B; Pastore D; Picardi M; Bonini A; Chierichini A; Fanci R; Caramatti C; Invernizzi R; Mattei D; Mitra ME; Melillo L; Aversa F; Van Lint MT; Falcucci P; Valentini CG; Girmenia C; Nosari A
    Haematologica; 2006 Aug; 91(8):1068-75. PubMed ID: 16885047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
    Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
    J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Invasive fungal infections in liver transplant recipients: analysis of 21 cases].
    Miguélez M; Lumbreras C; Herrero JA; Aguado JM; del Palacio A; Colina F; Gómez R; Lizasoain M; Moreno E; Rodríguez-Noriega A
    Med Clin (Barc); 1998 Mar; 110(11):406-10. PubMed ID: 9608495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
    Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
    Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999.
    Lortholary O; Charlemagne A; Bastides F; Chevalier P; Datry A; Gonzalves MF; Michel G; Tilleul P; Veber B; Herbrecht R
    J Antimicrob Chemother; 2004 Aug; 54(2):456-64. PubMed ID: 15231769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.